Q-omics provides the consensus-scored ZDHHC11 profile across patient tissues and cancer cell-line models. ZDHHC11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ZDHHC11 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZDHHC11 RNA expression shows 16,691 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, THCA, and UVM as cancer lineages where ZDHHC11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC11 survival associations across molecular data types. ZDHHC11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC11 RNA expression–survival associations across cancer types. High ZDHHC11 expression shows unfavorable associations in COAD, ACC, MESO, UVM and UCEC, but favorable associations in HNSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ZDHHC11 RNA expression.
This table summarizes ZDHHC11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZDHHC11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC11 shows lower tumor expression in THCA and LUAD and higher tumor expression in CHOL, READ, STAD and COAD. The THCA box plot shows higher ZDHHC11 RNA expression in normal versus tumor tissue (log2 FC = −0.550, t-test p < 0.001).
This table shows molecular features associated with ZDHHC11 in patient tissues and cancer cell lines. In patient samples, ZDHHC11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
